ACTION IA Clinical Trial In Overt Nephropathy I. A trial that asked whether pharmacologic inhibition of advanced glycated endproduct (AGE) production with pimagedine slowed the progression of chronic renal disease in type 1 diabetics.
Conclusion No. Pimagedine patients tended to have a lower risk of doubling of serum creatinine (not statistically significant). Pimagedine’s effect on serum lipids was statistically significant—reducing triglycerides and LDL-cholesterol, and urine protein